Predictive validity of pharmacologic interventions in animal models of neuropathic pain

Scandinavian Journal of Pain

Volumn 2, Issue 4, 2011, Pages 178-184

  Honoré, Per Hartvig ^a   Basnet, Anna ^a   Kristensen, Pernille ^a   Andersen, Lene Munkholm ^a   Neustrup, Signe ^a   Møllgaard, Pia ^a   Eljaja, Laila ^a   Bjerrum, Ole J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animal models; Neuropathic pain; Pharmacotherapy; Predictive validity; Spared nerve injury model; Spinal nerve ligation model

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMPA RECEPTOR ANTAGONIST; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYTOKINE; GABAPENTIN; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; LAMOTRIGINE; MEXILETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; OPIATE; PHENYTOIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHESIS INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; SOMATOMEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG POTENCY; HUMAN; INFLAMMATION; MEDICAL LITERATURE; NERVE INJURY; NERVE TRACT; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 80053142484     PISSN: 18778860     EISSN: 18778879     Source Type: Journal    
DOI: 10.1016/j.sjpain.2011.06.002     Document Type: Review

References (93)

1. Blackburn-Munro G. Pain-like behaviours in animals - how human are they?. Trends Pharmacol Sci 2004, 25:299-305.
2. Scholz J., Woolf C.J. Can we conquer pain?. Nat Neurosci 2002, 5(Suppl.):1062-1067.
3. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol 2006, 2:95-106.
4. Pasero C. Pathophysiology of neuropathic pain. Pain Manag Nurs 2004, 5:3-8.
5. Alloui A., Zimmermann K., Mamet J., Duprat F., Noel J., Chemin J., Guy N., Blondeau N., Voielly N., Rubat-Coudert C., Borsotto M., Romey G., Heurteaux C., Reeh P., Eschalier A., Lazdunski M. TREK-1, a K+ channel involved in polymodal pain perception. EMBO J 2006, 25:2368-2376.
6. Costigan M., Woolf C.J. Pain: molecular mechanisms. J Pain 2000, 1:35-44.
7. Bridges D., Thompson S.W., Rice A.S. Mechanisms of neuropathic pain. Br J Anaesth 2001, 87:12-26.
8. Beydoun A., Backonja M.M. Mechanistic stratification of antineuralgic agents. J Pain Symptom Manage 2003, 25:S18-S30.
9. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353:1959-1964.
10. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000, 98:585-598.
11. Ren K., Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol 2008, 21:570-579.
12. Gordh T., Sharma H.S. Chronic spinal nerve ligation induces microvascular permeability disturbances, astrocytic reaction, and structural changes in the rat spinal cord. Acta Neurochir Suppl 2006, 96:335-340.
13. Attal N., Cruccu G., Haanpaa M., Hansson P., Jensen T.S., Nurmikko T., Sampaio C., Sindrup S., Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006, 13:1153-1169.
14. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Kalso E.A., Loeser J.D., Miaskowski C., Nurmikko T.J., Portenoy R.K., Rice A.S., Stacey B.R., Treede R.D., Turk D.C., Wallace M.S. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
15. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., Kermani P., Torkin R., Chen Z.Y., Lee F.S., Kraemer R.T., Nykjaer A., Hempstead B.L. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 2005, 25:5455-5463.
16. Nykjaer A., Lee R., Teng K.K., Jansen P., Madsen P., Nielsen M.S., Jacobson C., Kliemannel M., Schwarz E., Willnow T.E., Hempstead B.L., Petersen C.M. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004, 427:843-848.
17. Joshi S.K., Hernandez G., Mikusa J.P., Zhu C.Z., Zhong C., Salyers A., Wismer C.T., Chandran P., Decker M.W., Honore P. Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity. Neuroscience 2006, 143:587-596.
18. Lindia J.A., Kohler M.G., Martin W.J., Abbadie C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain 2005, 117:145-153.
19. Erichsen H.K., Hao J.X., Xu X.J., Blackburn-Munro G. A comparison of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain. Eur J Pharmacol 2003, 458:275-282.
20. Kiso T., Watabiki T., Tsukamoto M., Okabe M., Kagami M., Nishimura K., Aoki T., Matsuoka N. Pharmacological characterization and gene expression profiling of an L5/L6 spinal nerve ligation model for neuropathic pain in mice. Neuroscience 2008, 153:492-500.
21. Jensen T.S., Finnerup N.B. Management of neuropathic pain. Curr Opin Support Palliat Care 2007, 1:126-131.
22. Luo Z.D., Chaplan S.R., Higuera E.S., Sorkin L.S., Stauderman K.A., Williams M.E., Yaksh T.L. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001, 21:1868-1875.
23. Sutton K.G., Martin D.J., Pinnock R.D., Lee K., Scott R.H. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 2002, 135:257-265.
24. Field M.J., Hughes J., Singh L. Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. Br J Pharmacol 2000, 131:282-286.
25. Takasu K., Honda M., Ono H., Tanabe M. Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury. Br J Pharmacol 2006, 148:233-244.
26. Takeuchi Y., Takasu K., Honda M., Ono H., Tanabe M. Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. Eur J Pharmacol 2007, 556:69-74.
27. Hayashida K., DeGoes S., Curry R., Eisenach J.C. Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. Anesthesiology 2007, 106:557-562.
28. Hayashida K., Parker R., Eisenach J.C. Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. Anesthesiology 2007, 106:1213-1219.
29. Tanabe M., Takasu K., Kasuya N., Shimizu S., Honda M., Ono H. Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol 2005, 144:703-714.
30. Pan H.L., Eisenach J.C., Chen S.R. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 1999, 288:1026-1030.
31. Erichsen H.K., Blackburn-Munro G. Pharmacological characterisation of the spared nerve injury model of neuropathic pain. Pain 2002, 98:151-161.
32. Rode F., Brolos T., Blackburn-Munro G., Bjerrum O.J. Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. Psychopharmacology (Berl) 2006, 187:364-375.
33. Folkesson A., Honore P.H., Bjerrum O.J. Co-administered gabapentin and venlafaxine in nerve injured rats: Effect on mechanical hypersensitivity, motor function and pharmacokinetics. Scand J Pain 2010, 1:91-97.
34. Folkesson A., Honore P.H., Andersen L.M., Kristensen P., Bjerrum O.J. Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies. J Neural Transm 2010, 117:1377-1385.
35. Lee S.H., Kayser V., Desmeules J., Guilbaud G. Differential action of morphine and various opioid agonists on thermal allodynia and hyperalgesia in mononeuropathic rats. Pain 1994, 57:233-240.
36. Backonja M.M., Miletic G., Miletic V. The effect of continuous morphine analgesia on chronic thermal hyperalgesia due to sciatic constriction injury in rats. Neurosci Lett 1995, 196:61-64.
37. Kayser V., Lee S.H., Guilbaud G. Evidence for a peripheral component in the enhanced antinociceptive effect of a low dose of systemic morphine in rats with peripheral mononeuropathy. Neuroscience 1995, 64:537-545.
38. Lee Y.W., Chaplan S.R., Yaksh T.L. Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neurosci Lett 1995, 199:111-114.
39. Erichsen H.K., Hao J.X., Xu X.J., Blackburn-Munro G. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. Pain 2005, 116:347-358.
40. Ossipov M.H., Lopez Y., Nichols M.L., Bian D., Porreca F. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 1995, 199:83-86.
41. Mao J., Price D.D., Mayer D.J. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995, 61:353-364.
42. Bian D., Ossipov M.H., Ibrahim M., Raffa R.B., Tallarida R.J., Malan T.P., Lai J., Porreca F. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. Brain Res 1999, 831:55-63.
43. Iyengar S., Webster A.A., Hemrick-Luecke S.K., Xu J.Y., Simmons R.M. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004, 311:576-584.
44. Hayashida K., Eisenach J.C. Multiplicative interactions to enhance gabapentin to treat neuropathic pain. Eur J Pharmacol 2008, 598:21-26.
45. Liston D.R., Nielsen J.A., Villalobos A., Chapin D., Jones S.B., Hubbard S.T., Shalaby I.A., Ramirez A., Nason D., White W.F. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 2004, 486:9-17.
46. Kosasa T., Kuriya Y., Matsui K., Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999, 380:101-107.
47. Kosasa T., Kuriya Y., Yamanishi Y. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Jpn J Pharmacol 1999, 81:216-222.
48. Sugimoto H., Ogura H., Arai Y., Limura Y., Yamanishi Y. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 2002, 89:7-20.
49. Clayton B.A., Hayashida K., Childers S.R., Xiao R., Eisenach J.C. Oral donepezil reduces hypersensitivity after nerve injury by a spinal muscarinic receptor mechanism. Anesthesiology 2007, 106:1019-1025.
50. Millan M.J. Descending control of pain. Prog Neurobiol 2002, 66:355-474.
51. Kondo D., Saegusa H., Yabe R., Takasaki I., Kurihara T., Zong S., Tanabe T. Peripheral-type benzodiazepine receptor antagonist is effective in relieving neuropathic pain in mice. J Pharmacol Sci 2009, 110:55-63.
52. Bunch L., Erichsen M.N., Jensen A.A. Excitatory amino acid transporters as potential drug targets. Expert Opin Ther Targets 2009, 13:719-731.
53. Sung B., Lim G., Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 2003, 23:2899-2910.
54. Wu L.J., Zhuo M. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics 2009, 6:693-702.
55. Chizh B.A., Headley P.M. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 2005, 11:2977-2994.
56. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
57. Hu Y., Li W., Lu L., Cai J., Xian X., Zhang M., Li Q., Li L. An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. Pain 2010, 148:284-301.
58. Eljaja L., Bjerrum O.J., Honore P.H., Abrahamsen B. Effects of the excitatory amino acid transporter subtype 2 (EAAT-2) inducer ceftriaxone on different pain modalities in rat. Scand J Pain 2011, 2:132-136.
59. Syriatowicz J.P., Hu D., Walker J.S., Tracey D.J. Hyperalgesia due to nerve injury: role of prostaglandins. Neuroscience 1999, 94:587-594.
60. Gordh T., Sharma H.S., Alm P., Westman J. Spinal nerve lesion induces upregulation of neuronal nitric oxide synthase in the spinal cord. An immunohistochemical investigation in the rat. Amino Acids 1998, 14:105-112.
61. Winkler T., Sharma H.S., Gordh T., Badgaiyan R.D., Stalberg E., Westman J. Topical application of dynorphin A (1-17) antiserum attenuates trauma induced alterations in spinal cord evoked potentials, microvascular permeability disturbances, edema formation and cell injury: an experimental study in the rat using electrophysiological and morphological approaches. Amino Acids 2002, 23:273-281.
62. Ma W., Eisenach J.C. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 2002, 15:1037-1047.
63. Sweitzer S., Martin D., DeLeo J.A. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001, 103:529-539.
64. Sharma H.S., Winkler T., Stalberg E., Gordh T., Alm P., Westman J. Topical application of TNF-alpha antiserum attenuates spinal cord trauma induced edema formation, microvascular permeability disturbances and cell injury in the rat. Acta Neurochir Suppl 2003, 86:407-413.
65. Barker P.A. p75NTR is positively promiscuous: novel partners and new insights. Neuron 2004, 42:529-533.
66. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361:1545-1564.
67. Jansen P., Giehl K., Nyengaard J.R., Teng K., Lioubinski O., Sjoegaard S.S., Breiderhoff T., Gotthardt M., Lin F., Eilers A., Petersen C.M., Lewin G.R., Hempstead B.L., Willnow T.E., Nykjaer A. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci 2007, 10:1449-1457.
68. Willnow T.E., Petersen C.M., Nykjaer A. VPS10P-domain receptors - regulators of neuronal viability and function. Nat Rev Neurosci 2008, 9:899-909.
69. Fauchais A.L., Lalloue F., Lise M.C., Boumediene A., Preud'homme J.L., Vidal E., Jauberteau M.O. Role of endogenous brain-derived neurotrophic factor and sortilin in B cell survival. J Immunol 2008, 181:3027-3038.
70. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
71. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237:1154-1162.
72. Crowley C., Spencer S.D., Nishimura M.C., Chen K.S., Pitts-Meek S., Armanini M.P., Ling L.H., McMahon S.B., Shelton D.L., Levinson A.D. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994, 76:1001-1011.
73. Heumann R., Korsching S., Bandtlow C., Thoenen H. Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection. J Cell Biol 1987, 104:1623-1631.
74. Wells M.R., Vaidya U., Schwartz J.P. Bilateral phasic increases in dorsal root ganglia nerve growth factor synthesis after unilateral sciatic nerve crush. Exp Brain Res 1994, 101:53-58.
75. Zhou X.F., Deng Y.S., Chie E., Xue Q., Zhong J.H., McLachlan E.M., Rush R.A., Xian C.J. Satellite-cell-derived nerve growth factor and neurotrophin-3 are involved in noradrenergic sprouting in the dorsal root ganglia following peripheral nerve injury in the rat. Eur J Neurosci 1999, 11:1711-1722.
76. Ramer M.S., Bisby M.A. Adrenergic innervation of rat sensory ganglia following proximal or distal painful sciatic neuropathy: distinct mechanisms revealed by anti-NGF treatment. Eur J Neurosci 1999, 11:837-846.
77. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
78. Sharma H.S., Nyberg F., Gordh T., Alm P., Westman J. Topical application of insulin like growth factor-1 reduces edema and upregulation of neuronal nitric oxide synthase following trauma to the rat spinal cord. Acta Neurochir Suppl 1997, 70:130-133.
79. Sharma H.S., Nyberg F., Westman J., Alm P., Gordh T., Lindholm D. Brain derived neurotrophic factor and insulin like growth factor-1 attenuate upregulation of nitric oxide synthase and cell injury following trauma to the spinal cord. An immunohistochemical study in the rat. Amino Acids 1998, 14:121-129.
80. Sharma H.S., Westman J., Gordh T., Alm P. Topical application of brain derived neurotrophic factor influences upregulation of constitutive isoform of heme oxygenase in the spinal cord following trauma an experimental study using immunohistochemistry in the rat. Acta Neurochir Suppl 2000, 76:365-369.
81. Poyhia R., Xu M., Kontinen V.K., Paananen S., Kalso E. Systemic physostigmine shows antiallodynic effects in neuropathic rats. Anesth Analg 1999, 89:428-433.
82. Ramos K.M., Lewis M.T., Morgan K.N., Crysdale N.Y., Kroll J.L., Taylor F.R., Harrison J.A., Sloane E.M., Maier S.F., Watkins L.R. Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience 2010, 169:1888-1900.
83. Mogil J.S., Crager S.E. What should we be measuring in behavioral studies of chronic pain in animals?. Pain 2004, 112:12-15.
84. Vierck C.J., Hansson P.T., Yezierski R.P. Clinical and pre-clinical pain assessment: are we measuring the same thing?. Pain 2008, 135:7-10.
85. Mogil J.S., Graham A.C., Ritchie J., Hughes S.F., Austin J.S., Schorscher-Petcu A., Langford D.J., Bennett G.J. Hypolocomotion, asymmetrically directed behaviors (licking, lifting, flinching, and shaking) and dynamic weight bearing (gait) changes are not measures of neuropathic pain in mice. Mol Pain 2010, 6:34.
86. Gilron I., Max M.B. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 2005, 5:823-830.
87. Black D.R., Sang C.N. Advances and limitations in the evaluation of analgesic combination therapy. Neurology 2005, 65:S3-S6.
88. Davis M.P. What is new in neuropathic pain?. Support Care Cancer 2007, 15:363-372.
89. Sindrup S.H., Otto M., Finnerup N.B., Jensen T.S. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005, 96:399-409.
90. Kim K.J., Yoon Y.W., Chung J.M. Comparison of three rodent neuropathic pain models. Exp Brain Res 1997, 113:200-206.
91. Dowdall T., Robinson I., Meert T.F. Comparison of five different rat models of peripheral nerve injury. Pharmacol Biochem Behav 2005, 80:93-108.
92. Hansson E. Longterm pain, neuroinflammation and glial activation. Scand J Pain 2010, 1:67-72.
93. A receptor agonists in the rat spared nerve injury model of neuropathic pain. Eur J Pharmacol 2005, 516:131-138.